Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.1000 |
Strike | 95.00 |
Expiry date | 2024-06-21 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 34 |
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).